Randomized phase II study of cisplatin and etoposide versus temozolomide and capecitabine in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas (GEPNEC): A trial of the ECOG-ACRIN Cancer Research Group (EA2142).

被引：5
|
作者：
Eads, Jennifer Rachel
Catalano, Paul J.
Fisher, George A.
Klimstra, David S.
Zhang, Zheng
Rubin, Daniel
Iagaru, Andrei
Wong, Terence Z.
O'Dwyer, Peter J.
机构：
[1] Case Western Reserve Univ, Univ Hosp, Seidman Canc Ctr, Case Comprehens Canc Ctr, Cleveland, OH USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Stanford Univ, Stanford, CA 94305 USA
[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[5] Brown Univ, Providence, RI 02912 USA
[6] Stanford Univ, Sch Med, Stanford, CA 94305 USA
[7] Univ N Carolina, Chapel Hill, NC USA
[8] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS4149
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4149
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Front-line treatment with docetaxel, cisplatin and bevacizumab for patients with advanced/metastatic non-small, cell lung cancer: a multicenter phase II study of the Hellenic Oncology Research Group (HORG)
    Kentepozidis, Nikolaos
    Kotsakis, Athanasios
    Nikolaou, Christos
    Nintos, George
    Soultati, Aspasia
    Agelaki, Sofia
    Christophyllakis, Charalambos
    Agelidou, Maria
    Vamvakas, Lampos
    Georgoulias, Vassilis
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2014, 34 : S76 - S76
  • [42] Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pretreated with a non-platinum-based regimen in the first-line setting: A randomized phase II study of the Hellenic Oncology Research Group (HORG).
    Kentepozidis, Nikolaos K.
    Economopoulou, Panagiota
    Christophyllakis, Charalampos
    Chelis, Leonidas
    Polyzos, Aristidis
    Vardakis, Nikolaos
    Koinis, Filippos
    Nikolaou, Christos
    Georgoulias, Vassilis
    Kotsakis, Athanasios
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [43] Randomized phase III study of docetaxel (D) versus vinorelbine (V) for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group trial (WJTOG9904).
    Takeda, K
    Kudoh, S
    Nakagawa, K
    Takada, M
    Katakami, N
    Matsui, K
    Andoh, M
    Satoh, T
    Negoro, S
    Fukuoka, M
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 623S - 623S
  • [44] Randomized phase III trial of gemcitabine and cisplatin versus gemcitabine alone in patients with advanced non-small cell lung cancer (NSCLC) and a performance status (PS) 2: CAPPA-2 study
    Morabito, Alessandro
    Gebbia, Vittorio
    Cinieri, Saverio
    Vigano, Maria Grazia
    Bianco, Roberto
    Barbera, Santi
    Cavanna, Luigi
    De Marinis, Filippo
    Montesarchio, Vincenzo
    Costanzo, Raffaele
    Sandomenico, Claudia
    Montanino, Agnese
    Mancuso, Gianfranco
    Nacci, Angelo
    Giordano, Pasqualina
    Daniele, Gennaro
    Gridelli, Cesare
    Rocco, Gaetano
    Gallo, Ciro
    Di Maio, Massimo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Randomized phase III study of docetaxel (D) versus vinorelbine (V) for elderly patients (pts) with advanced non-small cell lung cancer (NSCLC): Results of a West Japan Thoracic Oncology Group Trial (WJTOG9904)
    Tamura, K
    Kudoh, S
    Negoro, S
    Nakagawa, K
    Takada, M
    Katakami, N
    Matsui, K
    Andoh, M
    Satoh, T
    Fukuoka, M
    LUNG CANCER, 2005, 49 : S33 - S33
  • [46] Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluorouracil, and Leucovorin Versus Oxaliplatin, 5-Fluorouracil, Leucovorin, and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Preoperative Chemoradiation: A Trial of the ECOG-ACRIN Research Group (E5204)
    Chakravarthy, A. Bapsi
    Zhao, Fengmin
    Meropol, Neal J.
    Flynn, Patrick J.
    Wagner, Lynne, I
    Sloan, Jeffrey
    Diasio, Robert B.
    Mitchell, Edith P.
    Catalano, Paul
    Giantonio, Bruce J.
    Catalano, Robert B.
    Haller, Daniel G.
    Awan, Rashid A.
    Mulcahy, Mary F.
    O'Brien, Timothy E.
    Santala, Roger
    Cripps, Christine
    Weis, John R.
    Atkins, James N.
    Leichman, Cynthia G.
    Petrelli, Nicholas J.
    Sinicrope, Frank A.
    Brierley, James D.
    Tepper, Joel E.
    O'Dwyer, Peter J.
    Sigurdson, Elin R.
    Hamilton, Stanley R.
    Cella, David
    Benson, Al B., III
    ONCOLOGIST, 2020, 25 (05): : E798 - E807
  • [47] Gemcitabine versus gemcitabine-carboplatin for patients with advanced non-small cell lung cancer and a performance status of 2: A prospective randomized phase II study of the Hellenic Cooperative Oncology Group
    Kosmidis, Paris A.
    Dimopoulos, Meletios-Athanasios
    Syrigos, Konstantinos
    Nicolaides, Costas
    Aravantinos, Gerasimos
    Boukovinas, Ioannis
    Pectasides, Dimitrios
    Fountzilas, George
    Bafaloukos, Dimitrios
    Bacoyiannis, Charalampos
    Kalofonos, Haralampos P.
    JOURNAL OF THORACIC ONCOLOGY, 2007, 2 (02) : 135 - 140
  • [48] Randomized phase II study of docetaxel (DOC) plus cisplatin (CDDP) versus DOC plus irinotecan in advanced non-small cell lung cancer (NSCLC); A West Japan Thoracic Oncology Group (WJTOG) study.
    Yamamoto, N
    Fukuoka, M
    Nakagawa, K
    Negoro, S
    Matui, K
    Kawahara, M
    Takada, Y
    Senba, H
    Kudo, S
    Ariyoshi, Y
    ANNALS OF ONCOLOGY, 2000, 11 : 107 - 107
  • [49] Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502
    Seto, Takashi
    Yamanaka, Takeharu
    Wasada, Izumi
    Seki, Nobuhiko
    Okamoto, Hiroaki
    Ogura, Takashi
    Shibuya, Masahiko
    Takiguchi, Yuichi
    Shinkai, Tetsu
    Masuda, Noriyuki
    Ichinose, Yukito
    Eguchi, Kenji
    Watanabe, Koshiro
    LUNG CANCER, 2010, 69 (02) : 213 - 217
  • [50] Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG)
    Kentepozidis, N.
    Economopoulou, P.
    Christofyllakis, Ch.
    Chelis, L.
    Polyzos, A.
    Vardakis, N.
    Koinis, F.
    Vamvakas, L.
    Katsaounis, P.
    Kalbakis, K.
    Nikolaou, Ch.
    Georgoulias, V.
    Kotsakis, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (03): : 317 - 325
12345